Pop Pop. Fizz Fizz. Oh What a Relief It Is. New CPIC Proton Pump Inhibitor Guidelines

<p>Ashley Kate Ragan, PharmD defines actionable proton pump inhibitor (PPI) drug-gene associations, discusses current pharmacogenomic PPI guidelines, including the 2018 Dutch Pharmacogenomic Working Group (DPWG) and 2020 Clinical Pharmacogenetic Implementation Consortium (CPIC) and reviews primary literature depicting CYP2C19 guided PPI dosing.</p> <p>For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs <a href='https://twitter.com/MayoPharmRes'>@MayoPharmRes</a> or the host, Garrett E. Schramm, Pharm.D., <a href='https://twitter.com/garrett_schramm'>@garrett_schramm</a> on Twitter!</p> <p>You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at <a href='https://ce.mayo.edu/'>https://ce.mayo.edu/</a> or on Twitter <a href='https://twitter.com/MayoMedEd'>@MayoMedEd</a>. </p>